CD19 and B-cell chronic lymphocytic leukemia: Early studies exploring the safety and feasibility of CD19-directed CAR T-cell therapy have generally included heterogeneous patient populations [i.e., they have enrolled patients with aggressive B-cell lymphoma, indolent B-cell lymphoma or chronic lymphocytic leukemia (CLL) in the same study] (2–4).